Researchers continue to innovate in nanomedicine to overcome obstacles in targeting metastatic cancer. New advancements include poly-L-histidine-coated mesoporous silica nanoparticles designed for targeted delivery of doxorubicin, enhancing therapeutic efficacy while minimizing side effects. These technologies aim to improve drug stability, uptake, and tumor specificity, addressing the limitations of conventional chemotherapy and offering promising avenues for precision oncology.